International Stem Cell Corp
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke, traumatic brain injury, and A… Read more
International Stem Cell Corp (ISCO) - Total Liabilities
Latest total liabilities as of September 2025: $9.06 Million USD
Based on the latest financial reports, International Stem Cell Corp (ISCO) has total liabilities worth $9.06 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
International Stem Cell Corp - Total Liabilities Trend (2012–2024)
This chart illustrates how International Stem Cell Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
International Stem Cell Corp Competitors by Total Liabilities
The table below lists competitors of International Stem Cell Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AETHLON MEDIC.NEW DL-001
STU:EJU
|
Germany | €1.34 Million |
|
Binah Capital Group, Inc. Warrants
NASDAQ:BCGWW
|
USA | $49.47 Million |
|
First Colombia Gold Corp
PINK:FCGD
|
USA | $162.38K |
|
Serinus Energy
PINK:SNUYF
|
USA | $50.04 Million |
|
Mercal Inmuebles Socimi SA
MC:YMEI
|
Spain | €22.22 Million |
|
IND.VAERDEN -A- (IDVA.SG)
STU:IDVA
|
Germany | €7.75 Billion |
|
Profithol S.A.
MC:SPH
|
Spain | €17.69 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down International Stem Cell Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how International Stem Cell Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for International Stem Cell Corp (2012–2024)
The table below shows the annual total liabilities of International Stem Cell Corp from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $9.10 Million | -4.95% |
| 2023-12-31 | $9.58 Million | -0.81% |
| 2022-12-31 | $9.65 Million | +1.27% |
| 2021-12-31 | $9.53 Million | +79.21% |
| 2020-12-31 | $5.32 Million | -44.05% |
| 2019-12-31 | $9.51 Million | +80.79% |
| 2018-12-31 | $5.26 Million | +9.56% |
| 2017-12-31 | $4.80 Million | +33.30% |
| 2016-12-31 | $3.60 Million | -35.05% |
| 2015-12-31 | $5.54 Million | -19.16% |
| 2014-12-31 | $6.86 Million | -2.32% |
| 2013-12-31 | $7.02 Million | +221.03% |
| 2012-12-31 | $2.19 Million | -- |